Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Utilization of an alternative docetaxel-based intraperitoneal chemotherapy regimen in patients with ovarian, fallopian tube or primary peritoneal carcinomaAmerican Journal of Clinical Oncology.  42:12-16. 2019
2018 Vulvar Cancer as a Result of GATA2 Deficiency, a Rare Genetic Immunodeficiency SyndromeObstetrics and Gynecology.  132:1112-1115. 2018
2018 Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinomaCell Growth and Differentiation.  16:813-824. 2018
2018 A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancerJournal of Nutrition.  148:1253-1260. 2018
2018 Lay patient navigators’ perspectives of barriers, facilitators and training needs in initiating advance care planning conversations with older patients with cancerJournal of Palliative Care.  33:70-78. 2018
2017 Values and worries of ovarian cancer patientsGynecologic Oncology.  147:433-438. 2017
2017 Implementation and Impact of Patient Lay Navigator-Led Advance Care Planning ConversationsJournal of Pain and Symptom Management.  53:682-692. 2017
2016 IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in miceJournal of Ovarian Research.  9:70. 2016
2016 IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in miceJournal of Ovarian Research.  9:1-11. 2016
2016 Patient-centered support in the survivorship care transition: Outcomes from the Patient-Owned Survivorship Care Plan InterventionCancer.  122:3232-3242. 2016
2016 Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinomaGynecologic Oncology.  142:25-29. 2016
2016 Endometrial Cancer: Using Evidence to Impact Practice and PolicyJournal for Nurse Practitioners.  12:395-402. 2016
2015 Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patientsGynecologic Oncology.  139:413-418. 2015
2014 A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapyGynecologic Oncology.  132:531-536. 2014
2014 Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study.Journal of Reproductive Medicine.  59:113-120. 2014
2013 Comparison of operative risks associated with radical hysterectomy in pregnant and nonpregnant womenJournal of Reproductive Medicine.  58:279-284. 2013
2013 Vulvar histoplasmosis as a rare cause of genital ulcerationObstetrics and Gynecology.  122:449-452. 2013
2013 The effect of the APPRISE mandate on use of erythropoiesis-stimulating agents and transfusion rates in patients with ovarian cancer receiving chemotherapyObstetrical and Gynecological Survey.  68:291-292. 2013
2013 The effect of the apprise mandate on use of erythropoiesis-stimulating agents and transfusion rates in patients with ovarian cancer receiving chemotherapyInternational Journal of Gynecological Cancer.  23:367-371. 2013
2013 Incidence of port site hernias and/or dehiscence in robotic-assisted procedures in gynecologic oncology patientsGynecologic Oncology.  131:123-126. 2013
2012 Smoothened antagonists reverse taxane resistance in ovarian cancerMolecular Cancer Therapeutics.  11:1587-1597. 2012
2012 Treatment of chemotherapy-induced anemia in ovarian cancer patients: Does the use of erythropoiesis-stimulating agents worsen survival?International Journal of Gynecological Cancer.  22:786-791. 2012
2012 Stem cell pathways contribute to clinical chemoresistance in ovarian cancerClinical Cancer Research.  18:869-881. 2012
2011 Cervical conization and the risk of preterm deliveryAmerican Journal of Obstetrics and Gynecology.  205:19-27. 2011
2011 The efficacy and toxicity of bevacizumab in combination with gemcitabine in patients with recurrent ovarian cancerClinical Ovarian Cancer.  4:34-37. 2011
2011 Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer modelGynecologic Oncology.  121:193-199. 2011
2010 Overcoming TRAIL resistance in ovarian carcinomaGynecologic Oncology.  119:157-163. 2010
2010 The clinical impact of computed tomography immediately following primary chemotherapy in patients with epithelial ovarian cancerClinical Ovarian Cancer.  3:52-55. 2010

Education And Training

  • Doctor of Medicine, University of Alabama at Birmingham 2005
  • UAB Hospital, Internship 2006
  • UAB Hospital, Residency 2009
  • UAB Hospital, Postdoctoral Fellowship 2012
  • Full Name

  • Kerri Bevis